Inovio Pharmaceuticals
INO
100 hedge funds and large institutions have $49.5M invested in Inovio Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 16 closing their positions.
96% more capital inflows, than outflows
Capital inflows: $10.3M | Capital outflows: $5.26M
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
35% more call options, than puts
Call options by funds: $1.71M | Put options by funds: $1.27M
4% more funds holding
Funds holding: 96 → 100 (+4)
1.91% more ownership
Funds ownership: 31.1% → 33.01% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.78M |
| 2 |
BlackRock
New York
|
+$1.48M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.19M |
| 4 |
GMT Capital
Atlanta,
Georgia
|
+$1.04M |
| 5 |
Deerfield Management
New York
|
+$631K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
-$2.16M |
| 2 |
Renaissance Technologies
New York
|
-$656K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$558K |
| 4 |
AGM
Alpine Global Management
New York
|
-$201K |
| 5 |
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$184K |
INO Hedge Fund Activity: Q3 2024 in Review
100 of the 6,989 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2024, worth a combined $49.5M — down 24% from $65.1M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new INO positions and 16 closed out — a net gain of 6 holders — while 27 added to existing stakes and 20 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.78M. The largest seller was Deep Track Capital, cutting an estimated $2.16M.
- 100 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2024, up from 96 in Q2 2024.
- Funds reported $49.5M of Inovio Pharmaceuticals stock for Q3 2024, down 24% quarter-over-quarter.
- 22 funds opened new Inovio Pharmaceuticals positions in Q3 2024 and 16 closed out, a net change of +6 holders.
- The largest Inovio Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $1.78M added.
- The largest Inovio Pharmaceuticals seller in Q3 2024 was Deep Track Capital, an estimated $2.16M sold.
Based on aggregated 13F filings for Q3 2024.